Komori
Share Issuance and Disposal4883Modalis Therapeutics CorporationPharmaceuticals

Notice Concerning the Large-Scale Exercise of the 19th Series Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Terms)

Of the 19th Stock Acquisition Rights issued to EVO FUND, rights equivalent to 3,440,000 shares were exercised between 7 July and 23 July 2026. As a result, the number of unexercised stock acquisition rights decreased from 196,500 to 162,100.

Worth reading
58In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
3440000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Large-scale exercise of stock acquisition rights with an exercise price adjustment clause issued through a third-party allotment

発行・処分する株式数

Number of shares delivered since the previous disclosure: 3,440,000 shares (3,440,000 new shares and 0 shares of treasury stock transferred)

Intended allottee
EVO FUND (allottee at the time of issuance)
Terms of the stock acquisition rights
Exercise price
¥33.0–¥34.0 (exercise prices during the period). Details of the adjustment clause and the floor price are Not disclosed
Number of Stock Acquisition Rights
Total issued: 240,000 rights; unexercised as of the previous disclosure: 196,500 rights; currently unexercised: 162,100 rights
Most recent equity financing
Issued on 12 June 2026: the 19th Stock Acquisition Rights (with Exercise Price Adjustment Clause) issued through a third-party allotment and the 2nd unsecured corporate bond (privately placed). The amount is Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalLarge-scale exercise of stock acquisition rights with an exercise price adjustment clause issued through a third-party allotment
Number of shares to be issued or disposed ofNumber of shares delivered since the previous disclosure: 3,440,000 shares (3,440,000 new shares and 0 shares of treasury stock transferred)
Intended allotteeEVO FUND (allottee at the time of issuance)
Total number of issued shares100,684,098 shares (as of the previous disclosure) → Not disclosed
Exercise price¥33.0–¥34.0 (exercise prices during the period). Details of the adjustment clause and the floor price are Not disclosed
Number of Stock Acquisition RightsTotal issued: 240,000 rights; unexercised as of the previous disclosure: 196,500 rights; currently unexercised: 162,100 rights
Most recent equity financingIssued on 12 June 2026: the 19th Stock Acquisition Rights (with Exercise Price Adjustment Clause) issued through a third-party allotment and the 2nd unsecured corporate bond (privately placed). The amount is Not disclosed
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the status of the large-scale exercise. No other reason is stated in the document.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Large-Scale Exercise of the 19th Series Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Terms) | Modalis Therapeutics Corporation (4883) timely disclosure | Komori